Loading...

Michael B. Nichol, PhD

TitleProfessor of Public Policy and Pharmaceutical Economics and Director of Graduate Health Programs. Sol Price School Vice Dean For Faculty Affairs
InstitutionUniversity of Southern California
DepartmentPublic Policy
AddressRGL 212
University Park Campus
Los Angeles CA 90089-0626
Phone+1 213 740 2355
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Nichol's research interests include Health Care Utilization, Health Insurance Design, Health Care Costs, Adherence Analysis, Pharmacoeconomics, Patient-Centered Outcomes, Health Care Management.

    Dr. Nichol began his health care career as a health planner with the Oregon State Health Planning and Development Agency. He became planning director, associate director, and then executive director of the Western Oregon Health Systems Agency, between the years of 1978 and 1984. During his tenure as executive director, the Agency developed the first physician-specific fee guide, which was distributed to the general public. In addition, the Agency sponsored multiple public hearings as a part of the Oregon Health Decisions project, which resulted in a set of health priorities for the Oregon Medicaid program.

    While directing the Department of Pharmaceutical Economics and Policy, Professor Nichol developed the Master of Science in Pharmaceutical Economics and Policy, which has become one of the premier graduate degrees in the field. He has served on a number of national boards and committees, including the National Commission on Quality Assurance Cardiovascular Work Group, the National Quality Forum’s National Voluntary Consensus Standards for the Reporting of Therapeutic Drug Management Quality Education and Adherence Technical Advisory Panel, the Agency for Healthcare Research and Quality (AHRQ) Healthcare Systems Research Study Section, and a study section for the Patient Centered Outcomes and Research Institute (PCORI). Professor Nichol was President of the USC Faculty during the 2008-2009 academic year.

    In addition to his present appointment as Professor of Health Policy, Dr. Nichol directs the Graduate Health Programs at the Price School of Public Policy. This program includes the Master in Health Administration and the Executive Master in Health Administration. In the last two years, both the MHA and the EMHA have been re-designed to create clear outcomes for student performance and career attainment. Dr. Nichol is also Professor of Pharmaceutical Economics and Policy in the School of Pharmacy.

    Dr. Nichol maintains an active research program enabled by federal and corporate grants. He has published more than 250 peer-reviewed articles and abstracts on a variety of health topics. He regularly consults for pharmaceutical and health insurance companies, as well as large physician groups within California.


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A. Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open. 2018 Aug 08; 8(8):e021900. PMID: 30093520.
      View in: PubMed
    2. Wang Y, Yan BP, Nichol M, Tomlinson B, Lee VWY. Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. Int J Cardiol. 2017 Dec 15; 249:18-24. PMID: 29121725.
      View in: PubMed
    3. Chen CX, Baker JR, Nichol M. Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. Value Health. 2017 09; 20(8):1074-1082. PMID: 28964439.
      View in: PubMed
    4. Payán DD, Lewis LB, Cousineau MR, Nichol M. Advocacy coalitions involved in California's menu labeling policy debate: Exploring coalition structure, policy beliefs, resources, and strategies. Soc Sci Med. 2017 03; 177:78-86. PMID: 28161674.
      View in: PubMed
    5. Curtis R, Baker J, Riske B, Ullman M, Niu X, Norton K, Lou M, Nichol M. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015 Dec; 90 Suppl 2:S11-6. PMID: 26619192.
      View in: PubMed
    6. Blume SW, Yeomans K, Allen-Ramey F, Smith N, Kim H, Lockey RF, Nichol M. Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice. J Manag Care Spec Pharm. 2015 Nov; 21(11):982-90. PMID: 26521110.
      View in: PubMed
    7. Navarro AE, Wysong J, DeLiema M, Schwartz EL, Nichol M, Wilber KH. Inside the Black Box: The Case Review Process of an Elder Abuse Forensic Center. Gerontologist. 2016 08; 56(4):772-81. PMID: 26248723; PMCID: PMC4944537 [Available on 08/01/17].
    8. Zhou ZY, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, Curtis RG, Poon JL, Lou M, Nichol M. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015 Jun; 18(6):457-65. PMID: 25660324.
      View in: PubMed
    9. Poon JL, Doctor JN, Nichol M. Longitudinal changes in health-related quality of life for chronic diseases: an example in hemophilia A. J Gen Intern Med. 2014 Aug; 29 Suppl 3:S760-6. PMID: 25029975; PMCID: PMC4124124.
    10. Kawatkar AA, Knight TK, Moss RA, Sikirica V, Chu LH, Hodgkins P, Haim Erder M, Nichol M. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD. Value Health. 2014 Sep; 17(6):661-8. PMID: 25236989.
      View in: PubMed
    11. Knight TK, Kawatkar A, Hodgkins P, Moss R, Chu LH, Sikirica V, Erder MH, Nichol M. Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population. Curr Med Res Opin. 2014 Jul; 30(7):1291-9. PMID: 24597796.
      View in: PubMed
    12. An J, Nichol M. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013 Oct; 51(10):879-87. PMID: 23929398.
      View in: PubMed
    13. Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol M. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303. PMID: 22807272.
      View in: PubMed
    14. Wallner LP, Frencher SK, Hsu JW, Chao CR, Nichol M, Loo RK, Jacobsen SJ. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int. 2013 Jun; 111(8):1245-52. PMID: 23320750.
      View in: PubMed
    15. Yen L, Wu J, Hodgkins PL, Cohen RD, Nichol M. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012 Nov-Dec; 18(9):701-12. PMID: 23206213.
      View in: PubMed
    16. Kawatkar AA, Hay JW, Stohl W, Nichol M. Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. PMID: 22718267.
      View in: PubMed
    17. Wallner L, Frencher S, Hsu JW, Loo R, Huang J, Nichol M, Jacobsen S. Prostate cancer screening trends in a large, integrated health care system. Perm J. 2012; 16(3):4-9. PMID: 23012592; PMCID: PMC3442760.
    18. Nichol M, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ. Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int. 2012 Aug; 110(3):353-62. PMID: 22077934.
      View in: PubMed
    19. Nichol M, Wu J, An JJ, Huang J, Denham D, Frencher S, Jacobsen SJ. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis. 2011 Sep; 14(3):253-61. PMID: 21537346.
      View in: PubMed
    20. Patino CM, Varma R, Azen SP, Conti DV, Nichol M, McKean-Cowdin R. The impact of change in visual field on health-related quality of life the los angeles latino eye study. Ophthalmology. 2011 Jul; 118(7):1310-7. PMID: 21458074; PMCID: PMC3129408.
    21. Yu AP, Yu YF, Nichol M. Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models. Value Health. 2010 Dec; 13(8):1038-45. PMID: 20946182.
      View in: PubMed
    22. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol M. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010 Sep-Oct; 13(6):846-52. PMID: 20561344.
      View in: PubMed
    23. Nichol M, Knight TK, Priest JL, Wu J, Cantrell CR. Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. J Am Pharm Assoc (2003). 2010 Jul-Aug; 50(4):496-507. PMID: 20621868.
      View in: PubMed
    24. Kymes SM, Plotzke MR, Li JZ, Nichol M, Wu J, Fain J. The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach. Am J Ophthalmol. 2010 Jul; 150(1):74-81. PMID: 20493465.
      View in: PubMed
    25. Benner JS, Nichol M, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010 May; 105(9):1276-82. PMID: 19912188.
      View in: PubMed
    26. Chapman RH, Benner JS, Girase P, Benigno M, Axelsen K, Liu LZ, Nichol M. Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin. 2009 May; 25(5):1247-60. PMID: 19344292.
      View in: PubMed
    27. Nichol M, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009 May; 181(5):2214-21; discussion 2221-2. PMID: 19296986.
      View in: PubMed
    28. Gwadry-Sridhar FH, Manias E, Zhang Y, Roy A, Yu-Isenberg K, Hughes DA, Nichol M. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther. 2009 Feb; 31(2):421-35. PMID: 19302915.
      View in: PubMed
    29. Nichol M, Knight TK, Wu J, Tang SS, Cherry SB, Benner JS, Hussein M. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health. 2009 Jun; 12(4):544-50. PMID: 19138308.
      View in: PubMed
    30. Cherry SB, Benner JS, Hussein MA, Tang SS, Nichol M. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009 Jun; 12(4):489-97. PMID: 18783393.
      View in: PubMed
    31. Cella D, Nichol M, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009 Jan-Feb; 12(1):124-9. PMID: 18647260.
      View in: PubMed
    32. Nichol M, Epstein JD. Separating gains and losses in health when calculating the minimum important difference for mapped utility measures. Qual Life Res. 2008 Aug; 17(6):955-61. PMID: 18615271.
      View in: PubMed
    33. Yu AP, Yu YF, Nichol M, Gwadry-Sridhar F. Delay in filling the initial prescription for a statin: a potential early indicator of medication nonpersistence. Clin Ther. 2008 Apr; 30(4):761-74; discussion 716. PMID: 18498924.
      View in: PubMed
    34. Epstein JD, Knight TK, Epstein JB, Bride MA, Nichol M. Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck. 2008 Feb; 30(2):178-86. PMID: 17694558.
      View in: PubMed
    35. Thiebaud P, Patel BV, Nichol M. The demand for statin: the effect of copay on utilization and compliance. Health Econ. 2008 Jan; 17(1):83-97. PMID: 17585395.
      View in: PubMed
    36. Patel BV, Leslie RS, Thiebaud P, Nichol M, Tang SS, Solomon H, Honda D, Foody JM. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008; 4(3):673-81. PMID: 18827917; PMCID: PMC2515427.
    37. Nichol M, Knight TK, Dow T, Wygant G, Borok G, Hauch O, O'Connor R. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother. 2008 Jan; 42(1):62-70. PMID: 18094348.
      View in: PubMed
    38. Nichol M, Knight TK, Epstein J, Honda DH, Tretiak R. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. J Manag Care Pharm. 2007 May; 13(4):360-71. PMID: 17506602.
      View in: PubMed
    39. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007 Jan-Feb; 10(1):3-12. PMID: 17261111.
      View in: PubMed
    40. Thiebaud P, Patel BV, Nichol M. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health. 2006 Nov-Dec; 9(6):361-8. PMID: 17076866.
      View in: PubMed
    41. Nichol M. The role of outcomes research in defining and measuring value in benefit decisions. J Manag Care Pharm. 2006 Aug; 12(6 Suppl B):S19-23; quiz S24-6. PMID: 17274693.
      View in: PubMed
    42. Nichol M. Medicare Part D and the challenge of a dynamic marketplace. Manag Care Interface. 2006 May; 19(5):17, 19. PMID: 16786966.
      View in: PubMed
    43. Thiebaud P, Patel BV, Nichol M, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005 Nov; 11(11):670-4. PMID: 16268750.
      View in: PubMed
    44. Nichol M, Zhang L. Depression and health-related quality of life in patients with rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res. 2005 Oct; 5(5):645-53. PMID: 19807590.
      View in: PubMed
    45. Yu YF, Nichol M, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health. 2005 Jul-Aug; 8(4):495-505. PMID: 16091027.
      View in: PubMed
    46. Nichol M, Shi S, Knight TK, Wallace DJ, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis Rheum. 2004 Dec 15; 51(6):996-1003. PMID: 15593358.
      View in: PubMed
    47. Sengupta N, Nichol M, Wu J, Globe D. Mapping the SF-12 to the HUI3 and VAS in a managed care population. Med Care. 2004 Sep; 42(9):927-37. PMID: 15319619.
      View in: PubMed
    48. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, Holst EM, Nichol M, Shi SG, Livengood KB, Walden S, Lubowski TJ. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004 Sep; 38(9):1357-62. PMID: 15238621.
      View in: PubMed
    49. Sullivan PW, Nichol M. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. Value Health. 2004 Jul-Aug; 7(4):402-12. PMID: 15449632.
      View in: PubMed
    50. Shi CW, Asch SM, Fielder E, Gelberg L, Nichol M. Consumer knowledge of over-the-counter phenazopyridine. Ann Fam Med. 2004 May-Jun; 2(3):240-4. PMID: 15209201; PMCID: PMC1466662.
    51. Sullivan PW, Follin SL, Nichol M. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis. Pharmacoeconomics. 2004; 22(14):929-42. PMID: 15362929.
      View in: PubMed
    52. Sullivan PW, Follin SL, Nichol M. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care. 2003 Dec; 41(12):1382-95. PMID: 14668671.
      View in: PubMed
    53. Shi CW, Asch SM, Fielder E, Gelberg L, Brook RH, Leake B, Shapiro MF, Dowling P, Nichol M. Usage patterns of over-the-counter phenazopyridine (pyridium). J Gen Intern Med. 2003 Apr; 18(4):281-7. PMID: 12709095; PMCID: PMC1494847.
    54. Burk CT, Gilderman A, Salas J, Berenbeim D, Nichol M. The impact of an over-the-counter migraine medication program on quality of life. Headache. 2003 Mar; 43(3):191-201. PMID: 12603637.
      View in: PubMed
    55. Nichol M, Harada AS. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis. A review. Pharmacoeconomics. 1999 Nov; 16(5 Pt 1):433-48. PMID: 10662391.
      View in: PubMed
    Michael's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _